Volume 16, Number 12—December 2010
Wildlife-associated Cryptosporidium fayeri in Human, Australia
Highlight and copy the desired format.
|EID||Waldron LS, Cheung-Kwok-Sang C, Power ML. Wildlife-associated Cryptosporidium fayeri in Human, Australia. Emerg Infect Dis. 2010;16(12):2006-2007. https://dx.doi.org/10.3201/eid1612.100715|
|AMA||Waldron LS, Cheung-Kwok-Sang C, Power ML. Wildlife-associated Cryptosporidium fayeri in Human, Australia. Emerging Infectious Diseases. 2010;16(12):2006-2007. doi:10.3201/eid1612.100715.|
|APA||Waldron, L. S., Cheung-Kwok-Sang, C., & Power, M. L. (2010). Wildlife-associated Cryptosporidium fayeri in Human, Australia. Emerging Infectious Diseases, 16(12), 2006-2007. https://dx.doi.org/10.3201/eid1612.100715.|
To the Editor: Molecular tools are essential for Cryptosporidium spp. identification, taxonomy, and epidemiology because of morphologic similarities between species within this genus. Molecular analyses have now identified 22 Cryptosporidium spp. and >40 cryptic species (i.e., genotypes) across all vertebrate classes (1). The myriad of potential Cryptosporidium spp. hosts, in conjunction with the robustness of the infectious stage (oocyst), means diverse Cryptosporidium spp. constantly circulate through the environment. This circulation increases the potential for disease from a diversity of contamination sources.
Human cryptosporidiosis is a global problem causing illness in young, elderly, immunocompromised, and immunocompetent persons in both industrialized and developing nations. The 2 most common etiologic agents, responsible for 90% of reported human infections, are C. hominis and C. parvum (2,3). Additional species identified as human pathogens are C. meleagridis, C. canis, C. felis, and the Cryptosporidium rabbit genotype (4). Each of these species was once thought to be specific for turkeys, dogs, cats, and rabbits, respectively. Incidental findings of C. muris, C. andersoni, C. suis, C. hominis monkey genotype, C. parvum mouse genotype, and Cryptosporidium cervine (W4), chipmunk I (W17), skunk, and horse genotypes have also been reported in humans (4). The pathogenicity of these zoonotic species and genotypes to humans remains unclear.
In July 2009, a 29-year-old woman who sought care because of prolonged gastrointestinal illness had a fecal test positive for Cryptosporidium spp. by the Remel ProSpecT Giardia/Cryptosporidium microplate assay (Thermo Fisher Scientific, Lenexa, KS, USA). Oocysts were purified from the specimen (5) and stained with the Cryptosporidium spp.–specific antibody CRY104 labeled with fluorescein isothiocyanate (Biotech Frontiers, North Ryde, Australia) for enumeration. A parasite load of 1.34 × 106 oocysts/g feces was determined by using epifluorescence microscopy at 400× magnification.
To identify Cryptosporidium spp., DNA was extracted (5), and a diagnostic fragment of the small subunit (SSU) rRNA) was amplified (6). Clones were screened to identify species and determine the possibility of mixed infection. Plasmids from 50 clones were recovered and digested with the enzyme SspI (New England Biolabs, Beverly, MA, USA) (6). Two different restriction profiles were visualized. The sequence from each of the restriction types was determined; profile 1 contained SspI fragment sizes of 33, 109, 247, and 441 bp; profile 2 had fragments of 33, 254, and 540bp. A BLAST search (www.ncbi.nlm.nih.gov/blast) confirmed the sequences as C. fayeri type 1 and type 2. These 2 sequences correspond to known heterogeneity within the SSU rRNA of C. fayeri (7).
The identification of C. fayeri by SSU rRNA was confirmed by the sequence of the actin gene (8), showing 99.8% similarity to C. fayeri (GenBank accession no. AF112570). Further analysis at the 60-kDa glycoprotein (gp60) locus was used to determine the Cryptosporidium subtype family (5). The MQ1022 gp60 sequence was 98% similar to C. fayeri subtype family IVa (9). Analysis of the microsatellite region further characterized isolate MQ1022 to C. fayeri subtype IVaA9G4T1R1. The nucleotide sequences generated in this study were submitted to GenBank under accession nos. HQ008932–HQ008934.
Because the patient was imunocompetent, the disease was believed to be self-limiting, and she was lost to follow-up. The patient resided in a national forest on the east coast of New South Wales, Australia, an area where marsupials are abundant. She had frequent contact with partially domesticated marsupials. Notably, C. fayeri has been identified in 6 Australian marsupial species. Identification of C. fayeri in a human patient is a concern for water catchment authorities in the Sydney region. The main water supply for Sydney, Warragamba Dam, covers 9,050 km2 and is surrounded by national forest inhabited by diverse and abundant marsupials. A previous study that investigated Cryptosporidium spp. in a wild eastern gray kangaroo (Macropus giganteus) population reported a prevalence of 6.7% (10). Oocyst shedding ranged from 20/g feces to 2.0 × 106/g feces (10). Subtype IVaA9G4T1R1 identified from the patient in this study has been characterized from eastern gray kangaroos in Warragamba Dam (9). Throughout the year, large groups of eastern gray kangaroos graze within riparian zones in the catchment. Such close proximity to the water presents a high possibility that the dam’s water is contaminated with oocysts from these animals.
The Cryptosporidium genus is diverse, both in species and suitable hosts. The mechanisms of host specificity remain unknown, but the frequency of Cryptosporidium spp. crossing the host barrier and becoming zoonoses is increasing. This increase indicates that Cryptosporidium spp. host specificity is not as stringent as previously thought.
We thank Jeremy McAnulty and Nicola Stephens for their assistance with sample collection. The positive fecal sample, MQ1022, was provided by Douglas Hanley, Moir Pathology, Sydney, New South Wales, Australia.
Funding for this research was provided through the Macquarie University Research Excellence Scholarship scheme.
- Fayer R. Taxonomy and species delimitation in Cryptosporidium. Exp Parasitol. 2010;124:90–7.
- Morgan-Ryan UM, Fall A, Ward LA, Hijjawi N, Sulaiman I, Fayer R, Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporididae) from Homo sapiens. J Eukaryot Microbiol. 2002;49:433–40.
- Xiao L, Ryan U. Cryptosporidiosis: an update in molecular epidemiology. Curr Opin Infect Dis. 2004;17:483–90.
- Chalmers RM, Davies AP. Minireview: clinical cryptosporidiosis. Exp Parasitol. 2010;124:138–46.
- Waldron LS, Ferrari BC, Power ML. Glycoprotein 60 diversity in C. hominis and C. parvum causing human cryptosporidiosis in NSW Australia. Exp Parasitol. 2009;122:124–7.
- Xiao L, Morgan UM, Limor J, Escalante A, Arrowood M, Shulaw W, Genetic diversity within Cryptosporidium parvum and related Cryptosporidium species. Appl Environ Microbiol. 1999;65:3386–91.
- Xiao L, Limor JR, Li L, Morgan U, Thompson RC, Lal AA. Presence of heterogeneous copies of the small subunit rRNA gene in Cryptosporidium parvum human and marsupial genotypes and Cryptosporidium felis. J Eukaryot Microbiol. 1999;46:44S–5S.
- Sulaiman IM, Lal AA, Xiao L. Molecular phylogeny and evolutionary relationships of Cryptosporidium parasites at the actin locus. J Parasitol. 2002;88:388–94.
- Power ML, Cheung-Kwok-Sang C, Slade M, Williamson S. Cryptosporidium fayeri: diversity within the gp60 locus of isolates from different marsupial hosts. Exp Parasitol. 2009;121:219–23.
- Power ML, Sangster NC, Slade MB, Veal DA. Patterns of Cryptosporidium oocyst shedding by eastern grey kangaroos inhabiting an Australian watershed. Appl Environ Microbiol. 2005;71:6159–64.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Liette S. Waldron, Macquarie University—Biology, North Ryde, Sydney, New South Wales 2109, Australia
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: August 29, 2011
- Page last updated: August 29, 2011
- Page last reviewed: August 29, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)